swedish drug firm astra shares rose crowns 690 first two hours trading stockholm bourse amid hopes its research into anti viral drugs may have promising results treatment acquired immune deficiency syndrome aids stockbrokers said shares which climbed amid heavy institutional buying also rose reaction optimistic assessment future products firm annual report which was released this week brokers enskilda fondkommission said report this month astra was world leader anti viral drugs although enskilda said astra had not made any breakthrough developing specific drug treat acquired immune deficiency syndrome noted investors were only now discovering firm approach area was promising clear astra has tradition anti viral research which should prove valuable fighting this disease report enskilda investment banking unit skandinaviska enskilda banken said company officials could not reached for comment causes today share rise reuter 